Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

Villaruz, Liza C.; Socinski, Mark A.

doi:10.1016/j.ejca.2015.12.022

Cited by 20 publications

(18 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanoparticles of albuminpaclitaxel are absorbed by tumor cells from which paclitaxel is subsequently released to kill tumor cells (11). Compared with standard paclitaxel, nab-paclitaxel has an average particle size of 130 nm with minimal risk of capillary blockage (12) and enhances delivery of the cytotoxic agent to cancer cells. This occurs via a receptor-mediated transport mechanism as nab-paclitaxel leaves the circulation and enters tissues quicker.…”

Section: Figure 2 Overall Survival (Os) Of 34 Patients Who Received mentioning

confidence: 99%

Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer

Gong

Sun

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Figure 2 Overall Survival (Os) Of 34 Patients Who Received mentioning

confidence: 99%

Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer

Gong

Sun

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Even with recent advances in diagnosis and clinical treatment, the five-year survival rate is only 15% (1). Non-small cell lung cancer (NSCLC), such as the A549 cell line, accounts for 85% of all lung cancer cases (2). Notably, most patients with NSCLC are diagnosed after having reached a terminal stage and developed metastases in adjacent or dis tant organs (3).…”

Section: Introductionmentioning

confidence: 99%

Angelicin inhibits human lung carcinoma A549 cell growth and migration through regulating JNK and ERK pathways

Yao

et al. 2016

Oncology Reports

View full text Add to dashboard Cite

Angelicin is a member of a well-known class of chemical photosensitizes that have anticancer proper-ties in several cancer cell lines. However, the effects and the potential underlying mechanisms of angelicin action on human lung cancer cells remain unclear. Here, we report that angelicin has an essential role in inhibiting human lung carcinoma growth and metastasis. We found that angelicin markedly induced cell apoptosis and arrested the cell cycle in vitro. Angelicin also inhibited the migration of non-small cell lung cancer (NSCLC) A549 cells in a Transwell assay in a dose-dependent manner. In addition, after angelicin treatment, the expression levels of Bax, cleaved caspase-3 and cleaved caspase-9 were increased, and Bcl-2 expression was decreased. Moreover, our results indicate that angelicin inhibits NSCLC growth not only by downregulating cyclin B1, cyclin E1 and Cdc2, which are related to the cell cycle, but also by reducing MMP2 and MMP9 and increasing E-cadherin expression levels. Furthermore, extracellular signal-regulated kinase (ERK)1/2 and c-Jun NH2-terminal protein kinase (JNK)1/2 phosphorylation increased in parallel with the angelicin treatments. The inhibition of ERK1/2 and JNK1/2 by specific inhibitors significantly abrogated angelicin-induced cell apoptosis, cell cycle arrest and migration inhibition. We established in vivo A549 cell transplant and metastasis models and found that angelicin exerted a significant inhibitory effect on A549 cell growth and lung metastasis. Overall, our results suggested that angelicin is able to inhibit NSCLC A549 cell growth and metastasis by targeting ERK and JNK signaling, which demonstrates potential for NSCLC therapy.

show abstract

“…The choices really reside between platinum-based therapy plus a taxane, including paclitaxel, docetaxel, and nab-paclitaxel, and a gemcitabine-containing regimen. [57][58][59][60][61] However, I think the evidence suggests that taxane-based therapy is a better approach than gemcitabine therapy. [57][58][59][60][61] Gemcitabine has some side-effect advantages that the taxanes do not have.…”

Section: Dr Socinskimentioning

confidence: 99%

“…[57][58][59][60][61] However, I think the evidence suggests that taxane-based therapy is a better approach than gemcitabine therapy. [57][58][59][60][61] Gemcitabine has some side-effect advantages that the taxanes do not have. When gemcitabine is used as a single agent, the most common adverse effects are nausea and vomiting, anemia, hepatic transaminitis, neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and peripheral edema.…”

Section: Dr Socinskimentioning

confidence: 99%

Best Practices in Treatment Selection for Patients with Advanced NSCLC

Socinski

Pennell

2016

Cancer Control

Self Cite

View full text Add to dashboard Cite

Worldwide, lung cancer is the most prevalent form of cancer, and its non-small-cell subtype constitutes up to 85% of cases. Overall, lung cancer is the most common cause of cancer-related death in the United States for both sexes, and its 5-year survival rate is 17%. It is a heterogeneous disease characterized by a variety of biomarkers and differing histologies. Non-small-cell lung cancer may be squamous or nonsquamous in nature and fueled by a number of oncodrivers. Obtaining sufficient tissue during biopsy to perform thorough biomarker testing is a challenge but essential for the modern, targeted therapeutic environment. Although platinum-based doublets still play a major role in first-line treatment, novel therapeutic agent targeting BRAF, EGFR, ALK, and ROS1, as well as agents targeting the T790M mutation, may offer options for patients whose disease fails to respond to initial therapy or relapses following an initial response. The emergence of immunotherapy as second-line standard therapy has changed the treatment paradigm. Some patients will have more favorable outcomes in the first-line setting with immunotherapy. However, managing lung cancer has become more complex than it was 15 years ago when the challenge of treatment was seen as being only binary, ie, small-cell vs non-small-cell disease.

show abstract

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

Cited by 20 publications

References 69 publications

Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer

Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer

Angelicin inhibits human lung carcinoma A549 cell growth and migration through regulating JNK and ERK pathways

Best Practices in Treatment Selection for Patients with Advanced NSCLC

Contact Info

Product

Resources

About